WebBTRX-335140. BTRX-335140, also known by its other developmental code names BTRX-140, CYM-53093, and NMRA-140, is an opioid antagonist medication which is under development for the treatment of depression. [1] [2] [3] It is specifically a selective κ-opioid receptor antagonist and is under development for major depressive disorder. WebJan 23, 2024 · BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. ...

Major Depressive Disorder Pipeline Insight Report 2024: …

WebNov 5, 2024 · BlackThorn Therapeutics is a clinical-stage biopharmaceutical company dedicated to transforming the lives of people with neurobehavioral disorders. BlackThorn has created a robust pipeline of ... WebJan 4, 2024 · BlackThorn Therapeutics Announces R&D Updates BTRX-335140 Poised to Enter Phase 2 Efficacy Studies and BTRX-323511 to Enter IND-enabling Studies Company Increasing Investment in Computational... china teflon heating wire factory

Blackthorn Therapeutics Stock Price, Funding, Valuation, …

Web BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. WebBlackThorn Therapeutics employees are showing high interest in Verafin , Dynamic Workplace , and Relativity, according to Bombora. Last updated: Mar 19, 2024 IT Spend by Aberdeen This year, BlackThorn Therapeutics is projected to spend $92.5K on IT, according to Aberdeen. UNLOCK PREMIUM DATA WITH DATABOOST WebBlackThorn Therapeutics Profile and History . Founded in 2013 and headquartered in San Francisco, California, BlackThorn Therapeutics, Inc. operates as a biopharmaceutical company. The Company develops targeted treatments for neurobehavioral disorders. grammy\\u0027s unholy performance